Incannex Announces Reverse Stock Split
Rhea-AI Summary
Incannex (Nasdaq: IXHL) approved a 1-for-30 reverse stock split to be effective 4:01 p.m. ET on February 26, 2026 and will trade on a split-adjusted basis on February 27, 2026.
The reverse split will convert each 30 pre-split shares into one post-split share, reducing outstanding shares from approximately 358,329,368 to about 11,944,313. No fractional-share cash payments will be made; fractional interests will be rounded up. Proportional adjustments will apply to equity awards and the stock incentive plan.
Positive
- 1-for-30 reverse split approved and effective February 26, 2026
- Outstanding shares reduced ~96.67% to ~11.94 million
- Equity awards and incentive plan will be adjusted proportionally
Negative
- Total authorized shares will not be reduced, allowing future issuance
- No cash payment for fractional shares; rounding up only
News Market Reaction – IXHL
On the day this news was published, IXHL declined 42.12%, reflecting a significant negative market reaction. Argus tracked a trough of -43.5% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $71M from the company's valuation, bringing the market cap to $98.18M at that time. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IXHL’s pre-news move was down, while momentum peers SCYX and CPIX showed gains of 6.23% and 10.97%, suggesting stock-specific dynamics rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Clinical data update | Positive | -0.6% | Phase 2 RePOSA results and liquidity update for IHL-42X program. |
| Jan 29 | Board appointments | Positive | -0.6% | Three additions to Clinical Advisory Board for PSX-001 development. |
| Jan 22 | Advisory board formed | Positive | +0.5% | Formation of Clinical Advisory Board for PSX-001 anxiety program. |
| Jan 15 | Industry award | Positive | -1.7% | R&D award recognition for obstructive sleep apnea program IHL-42X. |
| Jan 14 | Corporate update | Positive | +2.1% | Transformational 2025 progress and well-funded 2026 outlook summary. |
Recent history shows multiple positive clinical and corporate updates often followed by negative price reactions, with 3 divergences versus 2 aligned moves.
Over the last several months, Incannex reported positive Phase 2 data, strategic Clinical Advisory Board formations, an industry R&D award, and a well-funded 2026 outlook with > $70 million in cash and a $20 million buyback authorization. Despite these constructive updates, price reactions were mixed, with several positive catalysts followed by modest declines. Today’s reverse split announcement fits into a period of active corporate and clinical development alongside ongoing balance sheet reshaping.
Market Pulse Summary
The stock dropped -42.1% in the session following this news. A negative reaction despite the structural nature of the 1-for-30 reverse split would fit prior patterns where positive corporate updates sometimes preceded declines. The action consolidates roughly 358,329,368 shares into about 11,944,313 without changing total authorization, which may prompt sentiment-driven selling. Past mixed responses to good news suggest that technical pressures and perception of risk around ongoing losses could amplify downside moves.
Key Terms
reverse stock split financial
cusip technical
nasdaq capital market regulatory
AI-generated analysis. Not financial advice.
Incannex’s common stock is expected to begin trading on a post-split adjusted basis on February 27, 2026
MELBOURNE, Australia and NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, today announced that the board of directors of the Company approved a 1-for-30 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on May 27, 2025. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on February 26, 2026. The Company’s common stock will open for trading under a new CUSIP number 45333F 208 on The Nasdaq Capital Market (“Nasdaq”) on February 27, 2026, on a split-adjusted basis under the current ticker symbol “IXHL.” The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on Nasdaq.
The 1-for-30 Reverse Split will automatically convert each 30 current shares of the Company’s common stock into one share of common stock. No fractional shares will be issued in connection with the Reverse Split. Stockholders of record who otherwise would be entitled to receive fractional shares because they hold a number of shares not evenly divisible by the Reverse Split ratio will automatically be entitled to receive an additional fraction of a share of the Company’s common stock to round up to the next whole share. With respect to outstanding common stock held in “street name” through a bank, broker or other nominee, fractional shares will be rounded up at the participant level. Cash will not be paid for fractional shares.
The Reverse Split will reduce the number of shares of outstanding common stock from approximately 358,329,368 shares, the number of shares outstanding as of February 20, 2026, to approximately 11,944,313 shares. The total authorized number of shares will not be reduced. Proportional adjustments will also be made to the exercise prices of the Company’s outstanding equity awards, and to the number of shares issued and issuable under the Company’s stock incentive plan.
Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers’ particular processes, and will not be required to take any action in connection with the Reverse Split. For those stockholders holding physical stock certificates, the Company’s transfer agent, Computershare Trust Company, N.A., will send instructions for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number of shares.
About Incannex Healthcare Inc.
Incannex is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The Company is advancing three clinical-stage drug candidates based on evidence-based innovation, and supported by streamlined operations. Incannex's lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnea. In a Phase 2 development program, IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. Approved for Phase 2 clinical development, PSX-001 is an oral synthetic psilocybin treatment for the treatment of generalized anxiety disorder. Incannex's programs target disorders that have limited, inadequate, or no approved pharmaceutical treatment options. For additional information on Incannex, please visit our website at www.incannex.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than historical facts and relate to future events, future circumstances and Incannex's future performance. These statements are based on management's current assumptions, expectations, and beliefs. Examples of forward-looking statements in this press release include statements about, among other things: timing and effectiveness of the Reverse Split; Incannex's ability to regain or maintain compliance with the Nasdaq minimum bid price requirement and other listing requirements, and Incannex's future intentions regarding its efforts to maintain and/or regain compliance with applicable Nasdaq listing standards. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: that Incannex may fail to maintain the listing of the Company’s common stock on Nasdaq and to comply with applicable listing requirements; the closing price of the common stock may fall below
Investor & Media Contacts
CORE IR
(212) 655-0924
investors@incannex.com
media@incannex.com.au
